callout

Treatment with DACOGEN® (decitabine) for Injection should continue beyond first reponse and until disease progression.10

Consequences of Treatment Discontinuation

Continuing treatment with hypomethylating agents may ultimately alter the progression of the disease.8

  • Of 108 patients with MDS who were treated with decitabine in three phase II trials, 65 (60%) responded. Of these, 22 patients (20%) demonstrated a response to the initial treatment and received re-treatment with decitabine at time of disease recurrence.10
Committment to Treatment

Patients who responded to decitabine treatment in the phase III study had continued therapy for a median of 6 cycles.3 Treatment may be continued as long as the patient continues to benefit.

To learn more about the DACOGEN difference, watch our video about methylation and the mechanism of action of DACOGEN

References

IMPORTANT SAFETY INFORMATION

DACOGEN may cause fetal harm when administered to a pregnant woman. Women of childbearing potential should be advised to avoid becoming pregnant while using DACOGEN. Men should be advised not to father a child while receiving treatment with DACOGEN, and for 2 months afterwards. The most commonly occurring adverse reactions include neutropenia, thrombocytopenia, anemia, pyrexia, fatigue, nausea, cough, petechiae, constipation, diarrhea, and hyperglycemia.

DACOGEN is available by prescription only. Please see the important product information for DACOGEN for more information. This site does not contain everything that is known about DACOGEN. If you would like to know more, talk to your healthcare professional.

This web site contains information relating to various medical conditions and their treatment. Such information is provided for educational purposes only and is not meant to be a substitute for the advice of a physician or other health care professional. You should not use this information for diagnosing a health problem or disease. Individual responses to DACOGEN treatment may vary.

This site is intended for health care professionals in the United States only. The products discussed herein may have different product labeling in different countries.

All information collected in this Web site is held in strictest confidence and will only be used for purposes as specified and will not be sold or distributed to other parties.

 
Dacogen® is a registered trademark of SuperGen, Inc., Dublin, CA, U.S.A. used under license.
Distributed and marketed by Eisai Inc.
© 2008 Eisai Inc.
All rights reserved. DAC135-B 5/08